World's Best Scientists 2026 revealed!

Overview

Yongqian Shu is affiliated with Nanjing Medical University in China and has contributed extensively to the fields of medicine and biochemistry, genetics, and molecular biology. Their research primarily focuses on oncology, pulmonary and respiratory medicine, molecular biology, cancer research, and surgery.

Their work covers a range of main topics including:

  • Lung Cancer Treatments and Mutations
  • Lung Cancer Research Studies
  • Cancer Immunotherapy and Biomarkers
  • Colorectal Cancer Treatments and Studies
  • Gastric Cancer Management and Outcomes
  • Lung Cancer Diagnosis and Treatment
  • Cancer Genomics and Diagnostics

Yongqian Shu has published in prominent venues, with frequent publications in:

  • Journal of Clinical Oncology
  • SSRN Electronic Journal
  • Journal of Thoracic Oncology
  • Cancer Cell
  • Annals of Oncology

Their notable recent papers include:

  • "Exosomal circSHKBP1 promotes gastric cancer progression via regulating the miR-582-3p/HUR/VEGF axis and suppressing HSP90 degradation" (2020), Molecular Cancer
  • "Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study" (2021), Cancer Cell
  • "Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double-blind randomized phase 2 trial" (2021), Cancer Medicine
  • "The evolving landscape of N6-methyladenosine modification in the tumor microenvironment" (2021), Molecular Therapy
  • "Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial" (2024), Nature Medicine

Collaborations have played a role in their career, with frequent co-authors including:

  • Jiuwei Cui (8 collaborations)
  • Ying Cheng (6 collaborations)
  • Zhiyong Ma (6 collaborations)
  • Yi-Long Wu (5 collaborations)
  • Kangsheng Gu (5 collaborations)

Best Publications

  • Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

    Luis Paz-Ares;Mikhail Dvorkin;Yuanbin Chen;Niels Reinmuth

  • Role of hypoxia in cancer therapy by regulating the tumor microenvironment

    Xinming Jing;Fengming Yang;Chuchu Shao;Ke Wei

  • Serum MicroRNA Signatures Identified in a Genome-Wide Serum MicroRNA Expression Profiling Predict Survival of Non–Small-Cell Lung Cancer

    Zhibin Hu;Xi Chen;Yang Zhao;Tian Tian

  • Pyroptosis: A new frontier in cancer.

    Yuan Fang;Shengwang Tian;Yutian Pan;Wei Li

  • Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.

    Jing Huang;Jianming Xu;Yun Chen;Wu Zhuang

  • P53-regulated long non-coding RNA TUG1 affects cell proliferation in human non-small cell lung cancer, partly through epigenetically regulating HOXB7 expression

    Zhang Eb;Yin Dd;Sun M;Kong R

  • A genome-wide association study identifies two new lung cancer susceptibility loci at 13q12.12 and 22q12.2 in Han Chinese

    Zhibin Hu;Chen Wu;Yongyong Shi;Huan Guo

  • miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines

    Wei Zhu;Xia Shan;Tongshan Wang;Yongqian Shu

  • A Functional Genetic Variant in microRNA-196a2 Is Associated with Increased Susceptibility of Lung Cancer in Chinese

    Tian Tian;Yongqian Shu;Jiaping Chen;Zhibin Hu

  • Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial.

    Caicun Zhou;Gongyan Chen;Yunchao Huang;Jianying Zhou

  • Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis

    Wen Gao;Yue Yu;Hailong Cao;Hua Shen

  • Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial.

    Jin Li;Jin Li;Shukui Qin;Rui Hua Xu;Lin Shen

  • CircRNAs in cancer metabolism: a review

    Tao Yu;Yanfen Wang;Yu Fan;Na Fang

  • MiR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis.

    Wen Gao;Hua Shen;Lingxiang Liu;Jian Xu

  • Multiple functions of m 6 A RNA methylation in cancer

    Yutian Pan;Pei Ma;Yu Liu;Wei Li

  • Exosomal circSHKBP1 promotes gastric cancer progression via regulating the miR-582-3p/HUR/VEGF axis and suppressing HSP90 degradation

    Mengyan Xie;Tao Yu;Xinming Jing;Ling Ma

  • Decreased expression of the long non-coding RNA FENDRR is associated with poor prognosis in gastric cancer and FENDRR regulates gastric cancer cell metastasis by affecting fibronectin1 expression

    Tong-peng Xu;Ming-de Huang;Rui Xia;Xin-xin Liu

  • Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study)

    Lin Shen;Jin Li;Jianming Xu;Hongming Pan

  • Comprehensive Characterization of Molecular Differences in Cancer between Male and Female Patients

    Yuan Yuan;Lingxiang Liu;Hu Chen;Yumeng Wang;Yumeng Wang

  • Exosomal miRNAs and miRNA dysregulation in cancer-associated fibroblasts.

    Fengming Yang;Zhiqiang Ning;Ling Ma;Weitao Liu

Frequent Co-Authors

Hongbing Shen
Hongbing Shen Nanjing Medical University
Zhibin Hu
Zhibin Hu Nanjing Medical University
Guangfu Jin
Guangfu Jin Nanjing Medical University
Rui-Hua Xu
Rui-Hua Xu Sun Yat-sen University
Yang Sun
Yang Sun Nanjing University
Jifeng Feng
Jifeng Feng Nanjing Medical University
Jianming Xu
Jianming Xu Zhejiang University
Caicun Zhou
Caicun Zhou Tongji University
Yi-Long Wu
Yi-Long Wu Guangdong Provincial People’s Hospital
Yi Ba
Yi Ba Beijing Institute of Genomics

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative or complementary online degrees can expand your career options in healthcare beyond traditional medical school. Many students pursue advanced online degrees that offer flexibility, affordability, and strong job prospects within the health sector.

For those interested in healthcare leadership, affordable online mha programs provide pathways into management and administration roles across hospitals, clinics, and public health organizations.

Nursing professionals can further their education and advance patient care careers with the best online bsn to dnp programs, equipping them for top nursing practice and leadership positions.

Aspiring pharmacists can benefit from an online pharmd degree, designed for flexibility and accessibility, preparing graduates for diverse pharmacy careers in clinical and community settings.

Additionally, online schools for health information management are ideal for those interested in the increasingly vital field of health data, medical records, and information systems.

Each of these options represents a dynamic pathway to a rewarding healthcare career—often with shorter commitments and lower costs compared to a traditional medical degree.

Best Scientists Citing Yongqian Shu

Trending Scientists